← Back to Clinical Trials
Recruiting NCT06135311

NCT06135311 Optimal Pulse Width Used in Transcutaneous Electrical Nerve Stimulation for Treating Nocturnal Enuresis in Children

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06135311
Status Recruiting
Phase
Sponsor Albany Medical College
Condition Nocturnal Enuresis
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2023-10-24
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 5 Years
Max Age 17 Years
Study Type INTERVENTIONAL
Interventions
Pulse Width 260usPulse Width 50us

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 70 participants in total. It began in 2023-10-24 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Children referred to pediatric urology clinic for primary nocturnal enuresis will be screened for enrollment. Patients who fail will next be offered therapy with a bedwetting alarm device or a TENS unit as an alternative, and those who chose TENS therapy will be included in the study.The patients will be randomized into two groups of 35 patients each.Group 1 will be the high pulse width set at 260us. Group 2 will be the low pulse width set at 50us. The patients will be provided with a TENS unit and electrode pads and caretakers instructed on how to use the apparatus. The child's TENS unit will be set at a pulse width determined by randomization, frequency of 10Hz, and an intensity to be determined in the office based upon when the child feels sensitive to the TENS unit. The child will be randomized and will place the electrodes along the posterior tibial nerve on the medial ankle each night before bed time for 30 minutes for a total of 30 days. Diaries including nighttime incontinence episodes and a "wet sheet" scale (dry, damp, wet, soaked) will be recorded, along with any adverse reactions to the TENS unit. Patients will be followed up after one month of TENS with evaluation including the Bowel \& Bladder Questionnaire (BBQ), a validated tool for measuring symptoms in children with voiding dysfunction \[6\]; this questionnaire will be filled out prior to starting TENS treatment in order to compare the effect of treatment. The data will be collected at different time points (baseline and after 1 month of treatment) for each group by itself and the groups compared against each other using statistical analysis.

Eligibility Criteria

Inclusion Criteria: 1. Presenting with nocturnal enuresis (more than 1x a week) 2. Failed Behavioral modification treatment (limiting evening drinking, double voiding prior to bedtime, bowel habits, social anxiety factors) during the 30 day period prior to randomization 3. Ability to provide informed consent and assent and complete study requirements Exclusion Criteria: 1. Patients who have previously tried pharmacologic treatment for nocturnal enuresis, neuromodulation or other alternative therapy for urologic disorders within the past 30 days 2. Daytime incontinence symptoms 3. Known "high volume" voiders (determined from history) 4. Bedwetting episodes on the average of less than two times per week, 5. Medications predisposing to incontinence (eg, Lithium for bipolar disorder) 6. Other known voiding or neurologic disorders (eg, overactive bladder, myelomeningocele, interstitial cystitis, etc) 7. Secondary etiologies for nocturnal enuresis (eg, cystitis, obstructive sleep apnea, urinary fistulae, heart disease) 8. Any contraindications to usage of a TENS unit (pacemaker or other implantable device, lymphedema, pregnancy, malignancy, bleeding or clotting disorders, unhealthy tissue, seizure disorders, impaired cognition) 9. Any history of heart disease or complications

Contact & Investigator

Central Contact

Brenda Romeo, CCRC

✉ romeob@amc.edu

📞 518-262-3349

Principal Investigator

Adam Howe, MD

PRINCIPAL INVESTIGATOR

Albany Medical College

Frequently Asked Questions

Who can join the NCT06135311 clinical trial?

This trial is open to participants of all sexes, aged 5 Years or older, up to 17 Years, studying Nocturnal Enuresis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06135311 currently recruiting?

Yes, NCT06135311 is actively recruiting participants. Contact the research team at romeob@amc.edu for enrollment information.

Where is the NCT06135311 trial being conducted?

This trial is being conducted at Albany, United States.

Who is sponsoring the NCT06135311 clinical trial?

NCT06135311 is sponsored by Albany Medical College. The principal investigator is Adam Howe, MD at Albany Medical College. The trial plans to enroll 70 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology